• 1
    American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorders 4th edition. Washington : American Psychiatric Association, 1994; 1886.
  • 2
    Blair HT, Tinkelman A, Moita MA LeDoux JE. Associative plasticity in neurons of the lateral amygdala during auditory fear conditioning. Ann NY Acad Sci 2003; 985:485487.
  • 3
    Bliss TV, Collingridge GL. A synaptic model of memory: Long-term potentiation in the hippocampus. Nature 1993; 361:3139.
  • 4
    Boje KM, Wong G, Skolnick P. Desensitization of the NMDA receptor complex by glycinergic ligands in cerebellar granule cell cultures. Brain Res 1993; 603:207214.
  • 5
    Bouton ME. Context, ambiguity, and unlearning: Sources of relapse after behavioral extinction. Biol Psychiatry 2002; 52:976986.
  • 6
    Cahill L, Weinberger NM, Roozendaal B, McGaugh JL. Is the amygdala a locus of “conditioned fear”? Some questions and caveats. Neuron 1999; 23:227228.
  • 7
    Collinridge GL, Kehl SJ, McLennan H. Excitatory amino acids in synaptic transmission in the Schaffer collateral-commissural pathway of the rat hippocampus. J Physiol 1983; 224:2246.
  • 8
    Davis M, Meyers KM, Ressler KJ, Rothbaum BO. Facilitation of extinction of conditione fear by D-cycloserine. Curr Dir Psychol Sci 2005; 14:214219.
    Direct Link:
  • 9
    Davis M, Walker DL, Meyers KM. Role of the amygdala in fear extinction measured with potentiated startle. Ann NY Acad Sci 2003; 985:218232.
  • 10
    Duncan EJ, Szilagyi S, Schwartz MP, et al. Effects of D-cycloserine on negative symptoms of schizophrenia. Schizophr Res 2004; 71:239248.
  • 11
    D'Souza DC, Gil R, Cassello K, et al. IV glycine and oral D-cycloserine effects on plasma and CSF amino acids in healthy humans. Biol Psychiatry 2000; 47:450462.
  • 12
    Fakouhi TD, Jjee SS, Sramek JJ, et al. Evaluation of cycloserine in the treatment of Alzheimer's disease. J Geriatr Psychiatry Neurol 1995; 8:226230.
  • 13
    Falls WA, Miserendino MJD, Davis M. Extinction of fear-potentiated startle: Blockade by infusion of an NMDA antagonist into the amygdala. J Neurosci 1992; 12:854863.
  • 14
    Fanselow MS, LeDoux JE. Why we think plasticity underlying Pavlovian fear conditioning occurs in the basolateral amygdale. Neuron 1999; 23:229232.
  • 15
    Foa EB, Franklin ME, Moser J. Context in the clinic: How well do cognitive-behavioral therapies and medications work in combination Biol Psychiatry 2002; 10:987997.
  • 16
    Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001; 158:13671377.
  • 17
    Goff DC, Herz L, Posever T, et al. A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology 2005; 179:144150.
  • 18
    Goff DC, Tsai G, Levitt J, et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 1999; 56:2127.
  • 19
    Golden RN. Making advances where it matters: Improving outcomes in mood and anxiety disorders. CNS Spectr 2004; 9:1422.
  • 20
    Guastella AJ, Dadds MR, Lovibond PF, Mithcell P, Richardson G. A randomized controlled trial of the effect of D-cycloserine on exposure therapy for spider fear. J Psychiatr Res; In press.
  • 21
    Guastella AJ, Lovibon P, Dadds MR, Mitchell P. A randomized controlled trial of the effect of D-cycloserine on extinction and fear-conditioning in humans. Behav Res Ther; In press.
  • 22
    Guy W. ECDEU assessment manual for psychopharmacology: Publication ADM 76-338. Washington : US Department of Health, Education and Welfare 1976; 217222.
  • 23
    Hebb DO. The organization of behavior. New York : Wiley, 1949; 1535.
  • 24
    Hofmann SG, Meuret AE, Smith JA, et al. Augmentation of exposure therapy for social anxiety disorder with D-Cycloserine. Arch Gen Psychiatry 2006; 63:298304.
  • 25
    Jahr CE, Stevens CF. Calcium permeability of the N-methyl-D-aspartate receptor channel in hippocampal neurons in culture. Proc Natl Acad Sci USA 1993; 90:115731577.
  • 26
    Kessler RC, McGonagle KA, Shanyang Z, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 1994; 51:819.
  • 27
    Laake K, Oeksengaard AR. D-cycloserine for Alzheimer's disease. Cochrane Database Syst Rev 2002; 2: CD003153.
  • 28
    Land C, Riccio DC. D-Cycloserine: Effects on long-term retention of a conditioned response and on memory for contextual attributes. Neurobiol Learn Mem 1999; 72:158168.
  • 29
    Lao J, Wang Y, Yasuda RP, Dunah AW, Wolfe BB. The majority of N-methyl-D-aspartate receptor complexes in adult rat cerebral cortex contain at least three different subunits (NR1/NR2A/NR2B). Mol Pharmacol 1997; 51:7986.
  • 30
    Laube B, Kuhse H, Betz H. Evidence for a tetrameric structure of recombinant NMDA receptors. J Neurosci 1998; 18:29542961.
  • 31
    Ledgerwood L, Richardson R, Cranney J. D-cycloserine facilitates extinction of conditioned fear as assessed by freezing in rats. Behav Neurosci 2003; 117:341349.
  • 32
    Ledgerwood L, Richardson R, Cranney J. D-cycloserine and the facilitation of conditioned fear: Consequences for reinstatement. Behav Neurosci 2004; 118:505513.
  • 33
    Lee HJ, Choi JS, Brown TH, Kim JJ. Amygdalar NMDA receptors are critical for the expression of multiple conditioned fear responses. J Neurosci 2000; 21:41164124.
  • 34
    Lelong V, Dauphin F, Boulouard M. RS 67333 and D-cycloserine accelerates learning acquisition in the rat. Neuropharmacology 2001; 41:517522.
  • 35
    Li XF, Phillips R, LeDoux JE. NMDA and non-NMDA receptors contribute to synaptic transmission between the medial geniculate body and the lateral nucleus of the amygdala. Exp Brain Res 1995; 105:87100.
  • 36
    Liebowitz MR. Social phobia. Mod Probl Pharmacopsychiatry 1987; 22:141173.
  • 37
    Lisman J. A mechanism for the Hebb and the anti-Hebb processes underlying learning and memory. Proc Natl Acad Sci USA 1989; 86:95749578.
  • 38
    Liu L, Wong TP, Pozzza MF, et al. Role of NMDA receptor subtypes in governing the direction of hippocampal synaptic placticity. Science 2004; 304:10211024.
  • 39
    Lynch G, Larson J, Kelso S, Barrionuevo G, Schottler F. Intracellular injections in EGTA block induction of hippocampal long-term potentiation. Nature 1983; 305:719721.
  • 40
    MacDermott AB, Mayer ML, Westbrook GL, Smith SJ, Baker JL. NMDA-receptor activation increases cytoplasmic calcium concentration in cultured spinal cord neurones. Nature 1986; 321:519522.
  • 41
    Malenka RC, Nicoll RA. Long-term potentiation — a decade of progress Science 1999; 285:18701874.
  • 42
    Myers KM, Davis M. Behavioral and neural analysis of extinction: A review. Neuron 2002; 36:567584.
  • 43
    Nair KGS, Epstein IG, Baron H, Mulinos MG. Absorption, distribution and excretion of cycloserine in man. Antibiot Annals; 1956; 3:136140.
  • 44
    Nishiyama M, Hong K, Mikoshiba K, Poo MM, Mato K. Ca2+ stores regulate the polarity and input specificity of synaptic medication. Nature 2000; 408:584588.
  • 45
    Nowak L, Bregestovski P, Ascher P, Herbert A, Prochiantz A. Magnesium gates glutamate-activated channels in mouse central neurons. Nature 1984; 307:462465.
  • 46
    Orr SP, Metzger LJ, Lasko NB, Macklin ML, Peri T, Pitman RK. De novo conditioning in trauma-exposed individuals with and without posttraumatic stress disorder. J Abnorm Psychol 2000; 109:290298.
  • 47
    Öst LG. One-session group treatment of spider phobia. Behav Res Ther 1996; 34:707715.
  • 48
    Otto MW, Smits JAJ, Reese HE. Combined psychotherapy and pharmacotherapy for mood and anxiety disorders in adults: Review and analysis. Clin Psychol (New York) 2005; 12:7286.
  • 49
    Otto MW, Basden S, Leyro TM, McHugh RK, Hofmann SG. Clinical perspectives on the combination of D-cycloserine and CBT for the treatment of anxiety disorders. Submitted to CNS Spectrum..
  • 50
    Parnas AS, Weber M, Richardson R. Effects of multiple exposures to D-cycloserine on extinction of conditioned fear in rats. Neurobiol Learn Mem 2005; 83:224231.
  • 51
    Physicians' Desk Reference, 58th Edition. Montvale , NJ : Medical Economics Co., 2004.
  • 52
    Posey DJ, Kem DL, Swiezy NB, Sweeten TL, Wiegand RE, McDougle CJ. A pilot study of D-cycloserine in subjects with autistic disorder. Am J Psychiatry 2004; 161:21152117.
  • 53
    Pussinen R, Sirvio J. Effects of D-cycloserine, a positive modulator of N-methyl-D-aspartate receptors, and ST 587, a putative alpha-1 adrenergic agonist, individually and in combination, on the non-delayed and delayed foraging behaviour of rats assessed in the radial arm maze. J Psychopharmacol 1999; 13:171179.
  • 54
    Quartermain D, Mower J, Rafferty MF, Herting RL, Lanthorn TH. Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention. Eur J Pharmacol 1994; 157:712.
  • 55
    Randolph C, Roberts JW, Tierney MC, Bravi D, Mourandian MM, Chase TN. D-cycloserine treatment of Alzheimer's disease. Alzheimer Dis Assoc Disord 1994; 8:198205.
  • 56
    Ressler KJ, Rothbaum BO, Tannenbaum L, et al. Cognitive enhancers as adjuncts to psychotherapy: Use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 2004; 61:11361144.
  • 57
    Richardson R, Ledgerwood L, Cranney J. Facilitation of fear extinction by D-cycloserine: Theoretical and clinical implications. Learn Mem 2004; 11:510516.
  • 58
    Richter-Levin G. The amygdala, the hippocampus, and emotional modulation of memory. Neuroscientist 2004; 10:3139.
  • 59
    Rodrigues SM, Schafe GE, LeDoux JE. Intra-amygdala blockade of the NR2B subunit of the NMDA receptor disrupts the acquisition but not the expression of fear conditioning. J Neurosci 2001; 21:68896896.
  • 60
    Rowland LM, Astur RS, Jung RE, Bustillo JR, Lauriello J, Yeo RA. Selective cognitive impairments associated with NMDA receptor blockade in humans. Neuropsychopharmacology 2005; 30:633639.
  • 61
    Santini E, Muller RU, Quirk GJ. Consolidation of extinction learning involves transfer from NMDA-independent to NMDA-dependent memory. J Neurosci 2001; 21:90099017.
  • 62
    Schwartz BL, Hashtroudi S, Herting RL, Schwartz P, Deutsch SI. D-Cycloserine enhances implicit memory in Alzheimer patients. Neurology 1996; 46:420424.
  • 63
    Tsai G, Falk W, Gunther J, Coyle J. Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment. Am J Psychiatry 1999; 156:467469.
  • 64
    Turner SM, Beidel DC, Dancu CV, Stanley MA. An empirically derived inventory to measure social fears and anxiety: The Social Phobia and Anxiety Inventory. J Consult Clin Psychol 1989; 1:3540.
  • 65
    Van Berckel BN, Hijman R, Van Der Linden JA, Westenberg HG, Van Ree JM, Kahn RS. Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients. Biol Psychiatry 1996; 40:12981300.
  • 66
    Walker DL, Davis M. The role of amygdala glutamate receptors in fear learning, potentiated startle, and extinction. Pharmacol Biochem Behav 2002:71:379392.
  • 67
    Walker DL, Ressler KJ, Lu KT, Davis M. Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. J Neurosci 2002; 22:23432351.
  • 68
    Yurgelun-Todd DA, Coyle JT, et al. Functional magnetic resonance imaging studies of schizophrenic patients during word production: Effects of D-cycloserine. Psychiatry Res 2005; 138:2331.
  • 69
    Zhu M, Nix DE, Adam RDM, Peloquin CA. Pharmacokinetics of cycloserine under fasting conditions and with high-fat meal, orange juice, and antacids. Pharmacotherapy 2001; 21:891897.